Product Information
TIVICAY 50 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $77.6356 per EA under NDC 49702022813. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 12, 2013.
Strength
50 mg/1
Manufacturer
ViiV Healthcare CompanyNDC
49702022813
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOLUTEGRAVIR SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA204790FDA Approved
8/12/2013
On Market Since
8/13/2013
Pharmacological Classes
Price Statistics
The NADAC for TIVICAY 50 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 105.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $77.6356 per EA |
|---|---|
| All-time high | $77.6627 (May 13, 2026) |
| All-time low | $37.7955 (Nov 28, 2013) |
| 52-week high | $77.6627 |
| 52-week low | $75.3480 |
| Median price | $59.1878 |
| Average price | $58.4596 |
| Largest weekly change | +7.9% (Feb 3, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dolutegravir sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ViiV Healthcare Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dolutegravir sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIVICAY 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TIVICAY 50 MG TABLET, manufactured by ViiV Healthcare Company, is $77.6356 per EA (NDC 49702022813), effective Sep 30, 2026.
How has the price of TIVICAY 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for TIVICAY 50 MG TABLET has risen 105.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TIVICAY 50 MG TABLET?
Since Nov 28, 2013, the NADAC for TIVICAY 50 MG TABLET has ranged from a low of $37.7955 (Nov 28, 2013) to a high of $77.6627 (May 13, 2026), with a median of $59.1878 per EA.
Are there cheaper alternatives to TIVICAY 50 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TIVICAY 50 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TIVICAY 50 MG TABLET?
TIVICAY 50 MG TABLET (NDC 49702022813) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.